Regeneron Pharmaceuticals
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 77 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.6 percentage points.
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 93.13% -0.60pp
- Institutions
- 1,751 +77
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-06-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 18 buys · 32 sells
| Name | Role | Stake |
|---|---|---|
| Leonard Schleifer | Co-Founder, President, CEO & Co-Chairman | 2.41% |
| George Yancopoulos | Co-Founder, President, Chief Scientific Officer & Co-Chairman | 1.16% |
| Andrew Murphy | Executive VP of Research & Co-Chief Scientific Officer | 0.05% |
| Joseph LaRosa | General Counsel | 0.04% |
| Daniel Van Plew | Executive VP and GM of Industrial Operations & Product Supply | 0.04% |
| George Sing | Independent Director | 0.03% |
| Christopher Fenimore | Chief Financial Officer | 0.03% |
| Michael Brown | Independent Director | 0.01% |
| Marion McCourt | Executive Vice President of Commercial | 0.01% |
| Robert Landry | Former Chief Financial Officer | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-03 | Jason Pitofsky | Senior Vice President | Open Market Disposition | -179 | $950.76 |
| 2026-11-03 | Jason Pitofsky | Senior Vice President | Derivative Exercise and Sale | -3,883 | $492.00–945.61 |
| 2026-11-02 | Andrew Murphy | Executive VP of Research & Co-Chief Scientific Officer | Other Disposition | -1,054 | -- |
| 2026-11-02 | Huda Zoghbi | Independent Director | Derivative Exercise and Sale | -7,439 | $380.95–971.06 |
| 2026-11-01 | Christopher Fenimore | Chief Financial Officer | Derivative Exercise and Sale | -4,258 | $381.92–950.50 |
| 2026-11-01 | Christopher Fenimore | Chief Financial Officer | Derivative Exercise and Retained | +1,742 | $381.92 |
| 2026-11-01 | Christine Poon | Lead Independent Director | Derivative Exercise and Sale | -7,830 | $376.69–971.31 |
| 2026-11-01 | George Sing | Independent Director | Open Market Disposition | -5,860 | $965.38–970.18 |
| 2026-11-01 | George Sing | Independent Director | Derivative Exercise and Sale | -15,269 | $376.69–965.38 |
| 2026-11-01 | Joseph LaRosa | General Counsel | Open Market Disposition | -869 | $965.41–966.11 |
| 2026-11-01 | Joseph LaRosa | General Counsel | Derivative Exercise and Sale | -12,283 | $381.92–965.41 |
| 2026-10-29 | Michael Brown | Independent Director | Derivative Exercise and Sale | -1,929 | $725.89–875.00 |
| 2026-10-29 | Marion McCourt | Executive Vice President of Commercial | Automatic Disposition | -1,132 | $869.43 |
| 2026-10-29 | Kathryn Guarini | Independent Director | Derivative Exercise and Sale | -400 | $719.37–900.00 |
| 2026-10-13 | Andrew Murphy | Executive VP of Research & Co-Chief Scientific Officer | Derivative Exercise and Sale | -17,000 | $381.92–781.47 |
| 2026-10-13 | Andrew Murphy | Executive VP of Research & Co-Chief Scientific Officer | Intent to Sell (Form 144) | -4,147 | $772.70 |
| 2026-09-02 | Marion McCourt | Executive Vice President of Commercial | Automatic Disposition | -2,346 | $850.00–857.39 |
| 2026-09-02 | Marion McCourt | Executive Vice President of Commercial | Intent to Sell (Form 144) | -1,131 | $857.00 |
| 2026-09-01 | Marion McCourt | Executive Vice President of Commercial | Intent to Sell (Form 144) | -1,215 | $850.00 |
| 2026-09-01 | Kathryn Guarini | Independent Director | Derivative Exercise and Sale | -400 | $719.37–850.00 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:42 · For reference only, not investment advice and not tailored to your situation.
Regeneron Pharmaceuticals discussion 0 comments